source
- FDA grants rapid approval to Revolution Medicines' pancreatic cancer drug RasonqueFDA approved Revolution Medicines' pancreatic cancer therapy Rasonque, just over a month after submission using a priority review voucher. The drug, formerly known as daraxonrasib, is for patients…
- FDA grants early approval to RevMed's pancreatic cancer drug RasonqueFDA granted early approval to Revolution Medicines' daraxonrasib, now named Rasonque, for pancreatic adenocarcinoma, arriving 6.5 months before the FDA deadline. The oral RAS inhibitor demonstrate…